keyword
https://read.qxmd.com/read/38655243/canadian-vaccine-safety-surveillance-reports-following-immunization-with-seasonal-influenza-vaccines-2021-2022
#1
JOURNAL ARTICLE
Elissa Giang, Yuhui Xu, Thivya Naganathan, Natalia Abraham, Marie-Thérèse Bawolak, Battouli Said Salim, Ashley Weeks, Amanda Shaw, Susanna Ogunnaike-Cooke
BACKGROUND: Seasonal influenza vaccines (SIV) authorized for use in Canada have all undergone rigorous regulatory assessments for safety and effectiveness. Serious adverse events following immunization (AEFI) can occur, though they are rare. Continuous safety surveillance of vaccines during the post-marketing phase is a critical component of vaccination programs. This enables the detection of rare, late onset, or unexpected adverse events. An updated safety summary following the introduction of any new vaccines and/or formulations to immunization programs is necessary for refining the risk-benefit profile of a specific vaccine and maintaining public confidence...
January 1, 2024: Canada Communicable Disease Report
https://read.qxmd.com/read/38655126/chronic-spontaneous-urticaria-preceded-by-localized-insulin-reactions-case-report
#2
Zoha K Momin, Jeffrey M Chambliss
Chronic spontaneous urticaria presents with wheals and/or angioedema for >6 weeks without any specific triggers. The incidence of chronic spontaneous urticaria is increased in patients with comorbid autoimmune conditions. Here, we present a case of chronic spontaneous urticaria in a 9-year-old with type 1 diabetes and autoimmune thyroid disease who first presented with insulin pump site reactions concerning an insulin-related allergy. The patient was successfully treated with antihistamines and later immunosuppression with resumption of insulin pump therapy and remission of chronic spontaneous urticaria symptoms 18 months after onset...
2024: SAGE Open Medical Case Reports
https://read.qxmd.com/read/38654448/an-update-on-the-use-of-antihistamines-in-managing-chronic-urticaria
#3
REVIEW
Yi-Kui Xiang, Jie Shen Fok, Indrashis Podder, Muhammed Burak Yücel, Defne Özkoca, Simon Francis Thomsen, Emek Kocatürk
INTRODUCTION: Urticaria, a mast cell-mediated skin disease, manifests as acute or chronic, with the latter divided into spontaneous and inducible types and requires individualized management, including identifying triggers and comorbidities. Antihistamines, particularly the second generation group, form the mainstay of primary treatment plans consisting of dosage adjustments and/or in combination with other treatment modalities depending on underlying disease control. AREAS COVERED: A literature search was conducted using 'antihistamines,' 'urticaria,' 'pharmacogenomics,' 'genomics,' 'biomarkers' and 'treatment response' as key words...
April 23, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38652814/immunologic-profiling-of-immune-related-cutaneous-adverse-events-with-checkpoint-inhibitors-reveals-polarized-actionable-pathways
#4
JOURNAL ARTICLE
Mario E Lacouture, Elena Goleva, Neil Shah, Veronica Rotemberg, Lukas Kraehenbuehl, Kwami F Ketosugbo, Taha Merghoub, Tara Maier, Alexander Bang, Stephanie Gu, Trina Salvador, Andrea P Moy, Taras Lyubchenko, Olivia Xiao, Clifton F Hall, Evgeny Berdyshev, James Crooks, Ryan Weight, Jeffrey A Kern, Donald Y M Leung
PURPOSE: Immune-related cutaneous adverse events (ircAEs) occur in ≥50% of patients treated with checkpoint inhibitors (CPI), but mechanisms are poorly understood. EXPERIMENTAL DESIGN: Phenotyping/biomarker analyses were conducted in 200 patients on CPIs (139 with ircAEs, 61 without, control) to characterize their clinical presentation and immunologic endotypes. Cytokines were evaluated in skin biopsies, skin tape strip (STS) extracts and plasma using real-time PCR and Meso Scale Discovery multiplex cytokine assays...
April 23, 2024: Clinical Cancer Research
https://read.qxmd.com/read/38650086/leukotriene-receptor-antagonists-as-adjuvant-therapy-of-antihistamines-in-chronic-urticaria-a-systematic-review-and-meta-analysis
#5
REVIEW
Ocílio Ribeiro Gonçalves, Vitor E A Ribeiro, Maria T L Galvão, Raquel Oliveira de Sousa Silva, Milene V S Sobral, Giovana S A Kojima, João L R Freitas, Victor G Soares, Benjamim B de Azevedo, Caroline Baima de Melo
Certain guidelines recommend a second-generation H1-antihistamine (AH) as first-line treatment for patients with chronic urticaria (CU). However, some patients show insufficient response to a standard dose of this therapy and might benefit from adding leukotriene receptor antagonists (LTA). Therefore, we aimed to perform a systematic review and meta-analysis comparing LTA plus antihistamines with antihistamines alone. We performed a systematic review and meta-analysis, searching PubMed, EMBASE, and Cochrane Central for randomized clinical trial (RCT) data comparing LTA plus AH treatment to AH alone in patients with CU...
April 22, 2024: International Journal of Dermatology
https://read.qxmd.com/read/38648933/-translated-article-use-of-antihistamines-during-omalizumab-therapy-in-chronic-urticaria-in-the-routine-clinical-practice-a-48-patient-observational-trial
#6
M Menéndez Sánchez, E Pérez Fernández, J L López Estebaranz, E Gómez de la Fuente
No abstract text is available yet for this article.
April 20, 2024: Actas Dermo-sifiliográficas
https://read.qxmd.com/read/38645800/rapid-response-of-omalizumab-resistant-chronic-urticaria-to-acalabrutinib
#7
Diamond R Guy, Alicia Mizes, Christopher T Richardson
No abstract text is available yet for this article.
May 2024: JAAD Case Reports
https://read.qxmd.com/read/38644777/how-relevant-are-eosinophils-to-chronic-spontaneous-urticaria-no-evidence-of-clinical-benefit-from-eosinophil-depletion-with-benralizumab
#8
EDITORIAL
Clive E H Grattan, Emek Kocatürk
No abstract text is available yet for this article.
April 22, 2024: British Journal of Dermatology
https://read.qxmd.com/read/38642709/efficacy-and-safety-of-systemic-corticosteroids-for-urticaria-a-systematic-review-and-meta-analysis-of-randomized-clinical-trials
#9
JOURNAL ARTICLE
Xiajing Chu, Jason Wang, Leonardo Ologundudu, Romina Brignardello-Petersen, Gordon H Guyatt, Paul Oykhman, Jonathan A Bernstein, Sarbjit S Saini, Lisa A Beck, Susan Waserman, Joseph Moellman, Dave A Khan, Moshe Ben-Shoshan, Diane R Baker, Eric T Oliver, Javed Sheikh, David Lang, Sameer K Mathur, Tonya Winders, Sanaz Eftekhari, Donna D Gardner, Lauren Runyon, Rachel N Asiniwasis, Emily F Cole, Jeffrey Chan, Kathryn E Wheeler, Kathryn P Trayes, Paul Tran, Derek K Chu
BACKGROUND: Short courses of adjunctive systemic corticosteroids are commonly used to treat acute urticaria and chronic urticaria flares (both with or without mast cell-mediated angioedema), but their benefits and harms are unclear. OBJECTIVE: To evaluate the efficacy and safety of treating acute urticaria or chronic urticaria flares with versus without systemic corticosteroids. METHODS: We searched MEDLINE, EMBASE, CENTRAL, CNKI, VIP, Wanfang, and CBM databases from inception to July 8, 2023 for randomized controlled trials of treating urticaria with versus without systemic corticosteroids...
April 18, 2024: Journal of Allergy and Clinical Immunology in Practice
https://read.qxmd.com/read/38642326/short-term-impact-of-exposure-to-ambient-air-volatile-organic-compounds-on-daily-clinic-visits-for-urticaria-in-kaohsiung-taiwan
#10
JOURNAL ARTICLE
Hui-Wen Tseng, Ling-Ying Lu
BACKGROUND: Air volatile organic compounds (VOCs) cause allergic reaction mainly via the respiratory tract or skin. OBJECTIVE: This study aimed to investigate the association between daily visits by patients with urticaria and short-term changes in exposure to ambient air VOCs. METHODS: The dependent variable was information from patients with urticaria at a medical center in Kaohsiung, Taiwan, from 2014/01/01 to 2018/07/31. The multivariable model included one-day average 75th percentile values of air VOCs and meteorologic data retrieved from Taiwan Air Quality Monitoring Network database, and was analyzed using a case-crossover study design and conditional logistic regression...
April 20, 2024: Asian Pacific Journal of Allergy and Immunology
https://read.qxmd.com/read/38638671/a-review-of-bruton-s-tyrosine-kinase-inhibitors-in-multiple-sclerosis
#11
REVIEW
Laura Airas, Robert A Bermel, Tanuja Chitnis, Hans-Peter Hartung, Jin Nakahara, Olaf Stuve, Mitzi J Williams, Bernd C Kieseier, Heinz Wiendl
Bruton's tyrosine kinase (BTK) inhibitors are an emerging class of therapeutics in multiple sclerosis (MS). BTK is expressed in B-cells and myeloid cells, key progenitors of which include dendritic cells, microglia and macrophages, integral effectors of MS pathogenesis, along with mast cells, establishing the relevance of BTK inhibitors to diverse autoimmune conditions. First-generation BTK inhibitors are currently utilized in the treatment of B-cell malignancies and show efficacy in B-cell modulation. B-cell depleting therapies have shown success as disease-modifying treatments (DMTs) in MS, highlighting the potential of BTK inhibitors for this indication; however, first-generation BTK inhibitors exhibit a challenging safety profile that is unsuitable for chronic use, as required for MS DMTs...
2024: Therapeutic Advances in Neurological Disorders
https://read.qxmd.com/read/38638409/does-chronic-urticaria-affect-quality-of-sleep-and-quality-of-life
#12
JOURNAL ARTICLE
Azza M Abdel-Meguid, Sara M Awad, Mostafa Noaman, Asmaa M Abdel Gawad, Doaa A E Abou-Taleb
BACKGROUND: Urticaria affects a wide range of daily activities and social relationships. It has a severe impact on quality of life (QOL) and causes psychological problems. OBJECTIVE: was to assess the impact of chronic urticaria (CU) on quality of sleep, the levels of depression, anxiety, QOL and their interaction with each other and their relation to disease related factors. PATIENTS AND METHODS: The study included 25 patients with CU and 25 healthy controls...
April 2024: Journal of Public Health Research
https://read.qxmd.com/read/38636107/comparative-analysis-of-adverse-drug-reactions-associated-with-new-antiseizure-medications-from-the-korea-adverse-event-reporting-system-database
#13
JOURNAL ARTICLE
Hyun Kyung Kim, Kyung Sik Jang, Dong Wook Kim
OBJECTIVE: This study aimed to compare and characterize the safety profiles of new antiseizure medications (ASMs) using a nationwide pharmacovigilance database from a long-term perspective in Korea. METHODS: We reviewed adverse event reports from the Korea Adverse Event Reporting System database between January 2013 and December 2022 for descriptive analysis of six new ASMs (lacosamide, levetiracetam, lamotrigine, oxcarbazepine, topiramate, and zonisamide). We investigated the frequency and characteristics of adverse drug reactions (ADRs) based on the MedDRA terminology, system organ classes, and modified WHO classification...
April 16, 2024: Epilepsy & Behavior: E&B
https://read.qxmd.com/read/38634840/trips-through-the-skin-reviewing-cutaneous-drug-reactions-to-psychedelics-and-hallucinogens
#14
REVIEW
Syed Minhaj Rahman, Yousef Salem, Aamir Hussain
<u> <i/> </u>Although psychedelic and hallucinogenic substances have gained popularity for therapeutic use, their dermatologic adverse effects are poorly characterized. This review characterizes the cutaneous reactions associated with psychedelic and hallucinogenic drugs. A review of PubMed and Scopus was conducted from the inception of databases to August 31, 2023. Search terms included drug names and classes (cannabis, MDMA, ecstasy, 3,4-methylenedioxymethamphetamine, psychedelics, hallucinogens, peyote, marijuana, lysergic acid diethylamide, LSD, ketamine, dimethyltryptamine, DMT, phencyclidine, PCP, dextromethorphan, psilocybin, and ayahuasca), and dermatosis terms (dermatitis, contact dermatitis, drug eruption, skin reaction, and urticaria)...
April 17, 2024: Dermatitis
https://read.qxmd.com/read/38634175/lin-cd117-cd34-fc%C3%AE%C2%B5ri-progenitor-cells-are-increased-in-chronic-spontaneous-urticaria-and-predict-clinical-responsiveness-to-anti-ige-therapy
#15
JOURNAL ARTICLE
Katie Ridge, Barry Moran, P Abigail Alvarado-Vazquez, Jenny Hallgren, Mark A Little, Alan D Irvine, Cliona O'Farrelly, Jean Dunne, Conor M Finlay, Niall Conlon
BACKGROUND: Chronic spontaneous urticaria (CSU) is a common, debilitating skin disorder characterized by recurring episodes of raised, itchy and sometimes painful wheals lasting longer than 6 weeks. CSU is mediated by mast cells which are absent from peripheral blood. However, lineage- CD34hi CD117int/hi FcεRI+ cells in blood have previously been shown to represent a mast cell precursor. METHODS: We enumerated FcεRI- , FcεRI+ and FcεRIhi lineage- CD34+ CD117+ cells using flow cytometry in blood of patients with CSU (n = 55), including 12 patients receiving omalizumab and 43 not receiving omalizumab (n = 43)...
April 17, 2024: Allergy
https://read.qxmd.com/read/38634097/comment-on-case-of-benralizumab-induced-exacerbations-of-chronic-spontaneous-urticaria
#16
JOURNAL ARTICLE
Mustafa Ilker Inan, Yasemin Akgul Balaban
No abstract text is available yet for this article.
April 2024: Clinical Case Reports
https://read.qxmd.com/read/38626739/predicting-the-speed-of-response-to-omalizumab-in-chronic-spontaneous-urticaria
#17
JOURNAL ARTICLE
Zeynep Keskinkaya, Özge Kaya, Selda Işık Mermutlu, Zerrin Öğretmen
INTRODUCTION: Two distinct chronic spontaneous urticaria (CSU) endotypes, IgE-mediated autoallergic and IgG-mediated autoimmune, were defined based on the response patterns to omalizumab. However, the coexistence of IgE and IgG autoantibodies in a subset of patients might complicate the prediction of the treatment outcomes. This study aimed to evaluate the effectiveness and safety of omalizumab in CSU patients, focusing on the factors predicting the response patterns. METHODS: This was a retrospective cross-sectional single-center study investigating CSU patients treated with omalizumab for at least 6 months between September 2015 and February 2023...
April 16, 2024: International Archives of Allergy and Immunology
https://read.qxmd.com/read/38623363/-anisakis-simplex-and-urticaria-what-we-know-about-its-real-incidence-and-management-in-dermatological-settings
#18
JOURNAL ARTICLE
Sanja Javor, Donatella Bignardi, Matteo Borro, Cesare Massone
Acute or chronic infections have been described among causes of chronic urticaria (CU). Anisakidosis is a human disease caused by the ingestion of larval nematodes of the family Anisakidae. The infestation is acquired by eating raw seafood or undercooked fish and squid. There are considerable variations in the frequency of underlying causes in the different studies and in different countries, such as differences in diets and the prevalence of infections. Anisakis simplex has been recognized as a trigger of both acute and CU manifestations...
March 12, 2024: Dermatology Reports
https://read.qxmd.com/read/38623321/different-doses-and-courses-of-omalizumab-for-patients-with-chronic-spontaneous-urticaria-a-systematic-review-with-meta-analysis-and-trial-sequential-analysis
#19
JOURNAL ARTICLE
Haiyan Qin, Xianjun Xiao, Di Qin, Peiwen Xue, Huilin Liu, Ying Li, Yunzhou Shi
BACKGROUND: The stability, efficacy, and safety of omalizumab at different doses and regimens for chronic spontaneous urticaria (CSU) are yet to be studied. OBJECTIVE: A systematic review (SR) with meta-analysis (MA) and trial sequential analysis (TSA) was performed to assess the efficacy and safety of omalizumab in CSU. METHODS: Randomised controlled trials (RCTs) of administering omalizumab versus placebo for CSU were searched. Random-effects MAs were performed using planned subgroup analyses...
April 2024: World Allergy Organization Journal
https://read.qxmd.com/read/38623319/association-between-lipid-lowering-drugs-and-allergic-diseases-a-mendelian-randomization-study
#20
JOURNAL ARTICLE
Yinsong Xu, Yuanzhi Li
BACKGROUND: Several observational studies suggest a possible link between lipid-lowering drugs and allergic diseases. However, inferring causality from these studies can be challenging due to issues such as bias, reverse causation, and residual confounding. To investigate the potential causal effect of lipid-lowering drugs, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors and 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase (HMGCR) inhibitors, on allergic diseases (allergic asthma, allergic conjunctivitis, atopic dermatitis, allergic rhinitis, and allergic urticaria), we performed a Mendelian randomization (MR)-based study...
April 2024: World Allergy Organization Journal
keyword
keyword
2618
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.